South Africa Gestational Trophoblastic Disease Market Size & Outlook, 2026-2034
South Africa Gestational Trophoblastic Disease Market Insights
- As per Reed Intelligence insights, the South Africa Gestational Trophoblastic Disease Market stood at USD 7.51 Million in 2025 and is anticipated to grow to USD 14.62 Million by 2034.
- The South Africa market is expected to advance at a CAGR of 7.75% from 2026 through 2034.
- In 2025, Hydatidiform Mole accounted for the highest share of the Type market size.
- During the forecast period, Placental Site Trophoblastic Tumor is set to register the highest growth, making it the most lucrative Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, South Africa accounted for 0.96% of the global Gestational Trophoblastic Disease Market size.
- By 2034, United States is expected to lead the global Gestational Trophoblastic Disease Market in terms of market size.
- Within Middle East and Africa, United Arab Emirates is projected to dominate the regional Gestational Trophoblastic Disease Market size by 2034.
- South Africa is identified as the fastest-growing market in Middle East and Africa, anticipated to reach USD 14.7 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 7.51 Million |
| Market Size In 2034 | USD 14.62 Million |
| Largest segment | Hydatidiform Mole |
| Units | Revenue in USD Million |
| CAGR | 7.75% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Treatment |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South Africa Gestational Trophoblastic Disease Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydatidiform Mole | XX.x | XX.x | XX.x | 3.5 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Choriocarcinoma | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Placental Site Trophoblastic Tumor | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Africa Gestational Trophoblastic Disease Market Treatment 2026-2034 (USD Million)
| Treatment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy | XX.x | XX.x | XX.x | 3.55 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Immunotherapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Africa Gestational Trophoblastic Disease Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 3.43 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
